1800-272-662
Shopping Cart 0
countryflagAU
Login

Nevro Corp

Healthcare US NVRO

NoneUSD
-(-%)

Last update at 2025-05-02T13:01:19.179680Z

Day Range

--
LowHigh

52 Week Range

13.9841.70
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap778.42M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-100.42200M
  • Revenue TTM422.84M
  • Revenue Per Share TTM11.82
  • Gross Profit TTM 276.37M
  • Diluted EPS TTM-2.87

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 4.26M -130.82600M -82.19700M -102.08700M -48.43700M
Minority interest - - - - -
Net income 3.00M -131.36000M -83.06500M -103.68600M -49.20500M
Selling general administrative 322.14M 309.31M 267.15M 305.81M 266.61M
Selling and marketing expenses - - - - -
Gross profit 276.37M 266.04M 249.90M 268.35M 273.32M
Reconciled depreciation 10.33M 8.68M 8.19M 7.80M 3.89M
Ebit -98.83600M -90.93400M -71.03800M -104.27900M -45.63000M
Ebitda -203.83600M -70.93400M -62.85200M -96.47900M -41.74300M
Depreciation and amortization -105.00000M 20.00M 8.19M 7.80M 3.89M
Non operating income net other 4.53M -0.14300M 2.46M 5.32M 3.71M
Operating income -98.83600M -90.93400M -62.85200M -96.47900M -41.74300M
Other operating expenses 505.20M 477.84M 424.90M 486.73M 429.03M
Interest expense 6.43M 19.75M 21.81M 10.93M 10.40M
Tax provision 1.26M 0.53M 0.87M 1.60M 0.77M
Interest income 4.02M 0.67M 2.96M 6.02M 4.87M
Net interest income -2.41100M -19.07800M -18.85000M -4.91100M -5.53000M
Extraordinary items - - - - -
Non recurring -105.00000M 20.00M - - -
Other items - - - - -
Income tax expense 1.26M 0.53M 0.87M 1.60M 0.77M
Total revenue 406.37M 386.90M 362.05M 390.25M 387.29M
Total operating expenses 375.20M 356.98M 312.75M 364.83M 315.07M
Cost of revenue 130.00M 120.86M 112.15M 121.91M 113.97M
Total other income expense net 103.10M -39.89200M -19.34500M -5.60800M -1.16400M
Discontinued operations - - - - -
Net income from continuing ops 3.00M -131.36000M -83.06500M -103.68600M -49.20500M
Net income applicable to common shares 3.00M -131.36000M -83.06500M -103.68600M -49.20500M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 602.41M 574.54M 789.43M 469.64M 463.12M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.98M 5.18M 4.17M 9.84M 6.62M
Total liab 278.53M 270.93M 400.97M 253.29M 217.63M
Total stockholder equity 323.88M 303.62M 388.46M 216.35M 245.48M
Deferred long term liab - - - - -
Other current liab 52.36M 50.20M 3.98M 54.56M 38.91M
Common stock 0.04M 0.04M 0.04M 0.03M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.03M 0.03M
Retained earnings -607.19700M -624.19300M -492.83300M -409.76800M -306.08200M
Other liab 2.16M 22.01M 3.34M 1.94M 2.83M
Good will - - - - -
Other assets 3.77M 5.10M 22.79M 14.29M 6.46M
Cash 120.37M 34.71M 44.60M 65.37M 51.27M
Cash and equivalents - - - - -
Total current liabilities 79.21M 82.20M 239.16M 70.61M 62.41M
Current deferred revenue - - 43.30M - -
Net debt 76.79M 132.00M 282.64M 115.37M 101.13M
Short term debt - - 168.78M - -
Short long term debt - - 168.78M - -
Short long term debt total 197.16M 166.71M 327.24M 180.75M 152.39M
Other stockholder equity 934.13M 928.14M 880.66M 626.40M 552.53M
Property plant equipment 22.27M 20.66M 13.53M 11.77M 12.80M
Total current assets 562.94M 531.20M 753.11M 422.05M 443.86M
Long term investments - - - - -
Net tangible assets 323.88M 303.62M 388.46M 216.35M 245.48M
Short term investments 254.01M 327.32M 543.37M 172.43M 213.28M
Net receivables 78.93M 70.47M 77.67M 82.83M 80.66M
Long term debt 186.87M 151.31M 141.77M 160.30M 152.39M
Inventory 99.64M 93.52M 83.30M 91.58M 92.03M
Accounts payable 26.85M 32.00M 23.11M 16.05M 23.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.09400M -0.36400M 0.60M -0.31300M -1.07700M
Additional paid in capital - - - - -
Common stock total equity 0.04M 0.04M 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity -607.19700M -624.19300M -492.83300M -409.76800M -306.08200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.77M 5.10M 4.65M 14.29M 6.46M
Deferred long term asset charges - - - - -
Non current assets total 39.47M 43.34M 36.32M 47.59M 19.26M
Capital lease obligations 10.30M 15.40M 16.69M 20.45M -
Long term debt total 186.87M 151.31M 141.77M 160.30M 152.39M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 71.83M 214.06M -371.34300M 43.30M 14.65M
Change to liabilities -27.95100M 26.35M -2.57000M 2.91M 5.89M
Total cashflows from investing activities 64.29M 201.72M -369.86800M 32.33M 6.43M
Net borrowings - -172.50000M 137.36M 189.75M 189.75M
Total cash from financing activities -2.45700M -169.38100M 346.90M 32.09M 7.75M
Change to operating activities -25.80500M 15.86M -2.78000M 7.67M -2.64600M
Net income 3.00M -131.36000M -83.06500M -103.68600M -49.20500M
Change in cash 85.66M -9.88700M -21.12600M 14.46M 8.22M
Begin period cash flow 35.32M 45.20M 66.33M 51.87M 43.65M
End period cash flow 120.98M 35.32M 45.20M 66.33M 51.87M
Total cash from operating activities 24.68M -41.88100M 1.19M -50.22500M -5.70800M
Issuance of capital stock 0.00000M 0.00000M 147.14M 35.15M 9.50M
Depreciation 10.33M 8.68M 8.19M 7.80M 3.89M
Other cashflows from investing activities - - 7.50M -7.50000M -7.50000M
Dividends paid - - - - -
Change to inventory -7.82800M -17.22500M 2.52M -0.93800M 3.85M
Change to account receivables -9.61100M 8.21M 3.37M -2.15300M -12.21400M
Sale purchase of stock 6.39M 11.18M 224.21M 35.15M 9.50M
Other cashflows from financing activities -2.45700M -8.06200M 199.76M -3.05700M -1.74200M
Change to netincome 61.27M 47.10M 50.20M 43.13M 38.14M
Capital expenditures 7.54M 12.34M 6.03M 3.47M 8.22M
Change receivables -9.61100M 8.21M 3.37M -2.15300M -12.21400M
Cash flows other operating -2.00700M 5.40M 10.68M 0.08M -2.18000M
Exchange rate changes - - - - -
Cash and cash equivalents changes 86.51M -9.54700M -21.77200M 14.20M 8.48M
Change in working capital -48.89000M 15.85M 10.79M -2.89000M -5.84400M
Stock based compensation 56.80M 44.37M 42.66M 41.70M 36.64M
Other non cash items 3.44M 13.26M 14.95M 7.91M 7.38M
Free cash flow 17.13M -54.22100M -4.83400M -53.69700M -13.92500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVRO
Nevro Corp		 - -% - - - 1.79 2.67 1.50 -7.5893
ABT
Abbott Laboratories		 -0.27 0.24% 110.28 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -14.43 4.02% 344.22 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.83 0.92% 89.06 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.52 2.17% 68.44 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Nevro Corp

1800 Bridge Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Mr. D. Keith Grossman Chairman, CEO & Pres 1960
Mr. Roderick H. MacLeod Chief Financial Officer 1967
Mr. Kashif Rashid Gen. Counsel, Corp. Sec. & Chief Compliance Officer 1974
Ms. Niamh Louise Pellegrini Chief Commercial Officer 1967
Mr. Patrick Schmitz VP of Operations 1960
Mr. Richard B. Carter Chief Accounting Officer 1971
Ms. Julie D. Dewey Chief Corp. Communications & Investor Relations Officer 1961
Mr. Michael Collier Carter VP of Global Sales 1972
Mr. Jon R. Shear VP of Corp. Devel. NA
Meredith Vornholt VP of Global Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.